Medical Diagnostic Developer MELA Sciences Appoints Senior Healthcare Finance Executive Robert W. Cook as CFO
April 09 2014 - 8:23AM
Business Wire
MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind®
system, an FDA approved optical diagnostic device that assists
dermatologists in the diagnosis of melanoma, appointed veteran
healthcare executive Robert W. Cook as Chief Financial Officer,
filling the position which had been vacant since December 31, 2013.
Mr. Cook brings over 20 years of experience in senior finance and
management leadership roles in the healthcare and pharmaceutical
industries, most recently as SVP and CFO of Immune Pharmaceuticals
Inc. (NASDAQ OMX First North and OTCQX:IMNP), a developer of
antibody therapeutics for cancer treatment, following its merger
with EpiCept Corporation (Nasdaq OMX Stockholm and OTCQX:EPCT).
“Bob brings a wealth of hands-on healthcare industry experience
and accomplishment across key functions such as finance, strategic
planning, business development and public company reporting," said
Rose Crane, MELA Sciences’ President and CEO. “We are very excited
to have attracted such an accomplished professional to support
MELA’s strategic transformation.”
“I am very pleased to become the newest member of the MELA
management team, and to be joining the Company at an important
point in its repositioning efforts,” commented Mr. Cook. “There is
significant potential at MELA, and I am eager to get started.”
Mr. Cook spent nine years as SVP and CFO at EpiCept where he was
responsible for finance and accounting, SEC reporting, treasury,
and budget, as well as IR/PR, information technology, facilities,
human resources and corporate administration. He had previously
served for six years as EVP and CFO of Pharmos Corporation, a
publicly traded biopharmaceutical company.
Mr. Cook began his career in financial services, initially at
The Chase Manhattan Bank, N.A. including several years as a
managing director responsible for developing business in the U.S.
pharmaceutical, medical device and hospital supply sectors. He
subsequently served as a Vice President in the Healthcare Group at
General Electric Capital Commercial Finance, focused on emerging
life science companies.
Mr. Cook earned his Bachelor’s degree in International Finance,
magna cum laude, from The American University in Washington,
D.C.
About MELA Sciences, Inc. www.melasciences.com
MELA Sciences is a medical device company developing dermatology
diagnostics utilizing state-of-the-art optical imaging. The
Company’s flagship product is the MelaFind® system, an FDA, PMA and
CE Mark approved, non-invasive diagnostic tool to aid
dermatologists in melanoma evaluation and diagnosis. The MelaFind®
system uses a variety of visible to near-infrared light waves to
evaluate skin lesions from the surface to 2.5 mm beneath the skin.
It provides images and data on the relative disorganization of a
lesion's cell structure that provides substantial additional
perspective to aid melanoma diagnosis. MELA is also exploring new
potential uses for its core imaging technology and algorithms.
Safe Harbor
This press release includes "forward-looking statements" within
the meaning of the Securities Litigation Reform Act of 1995. These
statements include but are not limited to our plans, objectives,
expectations and intentions and may contain words such as “seeks,”
“look forward,” and “there seems” that suggest future events or
trends. These statements are based on our current expectations and
are inherently subject to significant uncertainties and changes in
circumstances. Actual results may differ materially from our
expectations due to financial, economic, business, competitive,
market, regulatory and political factors or conditions affecting
the company and the medical device industry in general, as well as
more specific risks and uncertainties set forth in the company’s
SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any
or all of these forward-looking statements may prove to be
incorrect or unreliable. MELA Sciences assumes no duty to update
its forward-looking statements and urges investors to carefully
review its SEC disclosures available at www.sec.gov and
www.melasciences.com.
MediaMELA Sciences, Inc.Diana Garcia Redruello,
212-518-4226dgarcia@melasciences.comorInvestorsCatalyst
GlobalDavid Collins, Eric Lentini,
212-924-9800mela@catalyst-ir.com
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Apr 2023 to Apr 2024